Analyst consensus rating
Oramed Pharmaceuticals Analyst Rating: none
ORMP is rated none by 1 analysts with a $6.25 target. As of 2026-08-23.
Direct answer
Oramed Pharmaceuticals's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.25.
Forecast evidence checked August 23, 2026.
Get free Oramed Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.81
- Average price target
- $6.25
- High price target
- $6.25
- Low price target
- $6.25
- Low target gap
- +29.9%
- Target upside
- +29.9%
- High target gap
- +29.9%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $6.25.
How far are Oramed Pharmaceuticals's low and high targets from the recorded price?
The low target implies +29.9%, while the high target implies +29.9%.
How many analysts are included in Oramed Pharmaceuticals's consensus?
The verified consensus includes 1 analysts.
How is Oramed Pharmaceuticals's target upside or downside calculated?
The average target of $6.25 is divided by the recorded price of $4.81, then one is subtracted to produce +29.9%. This does not guarantee a future return.
When was Oramed Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.